Guardant Health, Inc.
HealthcareNASDAQ:GH · NASDAQ Global Select
+$0.72 today
Vol 1.45M · Avg 2.19M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$1.1B of revenue converted into -$433.2M of net income for the selected period. Gross margin is 64.9% and net margin is -40.2%, showing how much revenue survives after costs and taxes. EPS is $-3.39, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $982.0M +32.9% | $739.0M +31.0% | $563.9M +25.5% | $449.5M +20.3% | $373.7M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $349.0M +20.4% | $289.8M +27.6% | $227.1M +45.2% | $156.3M +27.2% | $122.9M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $633.0M +40.9% | $449.2M +33.3% | $336.9M +14.9% | $293.2M +16.9% | $250.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 64.5% +3.7pp | 60.8% +1.0pp | 59.7% -5.5pp | 65.2% -1.9pp | 67.1% | 9.8% | 28.9% | 38.3% |
| Research & Development | $364.2M +4.7% | $347.8M -5.3% | $367.2M -1.8% | $373.8M +42.0% | $263.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $706.1M +29.5% | $545.1M +20.8% | $451.0M -2.8% | $463.8M +16.4% | $398.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.1B +19.9% | $892.8M -1.0% | $901.6M +7.6% | $837.6M +26.6% | $661.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $39.7M -6.3% | $42.4M -1.2% | $42.9M +19.2% | $36.0M +61.5% | $22.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$373.9M +4.2% | -$390.1M +10.0% | -$433.3M +29.5% | -$614.9M -71.0% | -$359.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -38.1% +14.7pp | -52.8% +24.0pp | -76.8% +60.0pp | -136.8% -40.5pp | -96.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$436.3M +1.6% | -$443.6M +21.4% | -$564.7M -3.7% | -$544.4M -32.5% | -$411.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -44.4% +15.6pp | -60.0% +40.1pp | -100.1% +21.0pp | -121.1% -11.1pp | -110.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $34.1M -36.5% | $53.7M +51.8% | $35.4M +482.7% | $6.1M +54.4% | $3.9M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $3.9M +51.0% | $2.6M +0.1% | $2.6M +0.0% | $2.6M +0.0% | $2.6M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $18.8M +120.6% | $8.5M -90.1% | $86.0M +178.8% | -$109.1M -511.1% | $26.5M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$417.5M +4.0% | -$435.1M +9.1% | -$478.8M +26.7% | -$653.4M -70.0% | -$384.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -42.5% +16.4pp | -58.9% +26.0pp | -84.9% +60.5pp | -145.4% -42.5pp | -102.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$1.3M -198.4% | $1.3M +87.4% | $685.0K -39.9% | $1.1M +279.7% | $300.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$416.3M +4.6% | -$436.4M +9.0% | -$479.4M +26.8% | -$654.6M -61.4% | -$405.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | -42.4% +16.7pp | -59.0% +26.0pp | -85.0% +60.6pp | -145.6% -37.0pp | -108.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 +6.7% | -$4 +16.8% | -$4 +33.2% | -$6 -68.7% | -$4 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 +6.7% | -$4 +16.8% | -$4 +33.2% | -$6 -68.7% | -$4 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $125.4M +2.1% | $122.7M +9.6% | $112.0M +9.6% | $102.2M +0.9% | $101.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $125.4M +2.1% | $122.7M +9.6% | $112.0M +9.6% | $102.2M +0.9% | $101.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Exact Sciences Corporation
EXAS
$20.03B
Viatris Inc.
NASDAQ:VTRS
$19.19B
Solventum Corporation
NYSE:SOLV
$13.66B
Ascendis Pharma A/S
NASDAQ:ASND
$13.47B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.08B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.11B
ICON Public Limited Company
NASDAQ:ICLR
$11.19B
Revvity, Inc.
NYSE:RVTY
$11.12B
Encompass Health Corporation
NYSE:EHC
$10.07B
Qiagen N.V.
NYSE:QGEN
$7.64B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does GH generate?
Guardant Health, Inc. (GH) reported $982.02M of revenue in fiscal 2025.
Is GH profitable?
Guardant Health, Inc. (GH) reported -$416,277,000.00 of net income, with a net margin of -42.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.